12-month efficacy and safety of OROS® MPH in children and adolescents with attention-deficit/hyperactivity disorder switched from MPH

Hoare, Peter; Remschmidt, Helmut; Medori, Rossella; Ettrich, Christine; Rothenberger, Aribert; Santosh, Paramala; Schmit, Michael K.; Spender, Quentin; Tamhne, R.; Thompson, Margaret; Tinline, C.; Trott, Götz‐Erik

doi:10.1007/s00787-005-0486-3

Cited by 35 publications

(28 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Comparing the two studies by Hoare et al and Remschmidt et al (12 months vs 3 weeks), a similar incidence of abdominal pain (4% in both studies) and headache (10% vs 8%) was reported, while the incidence of tics doubled (8% vs 4%) 23 36…”

Section: Resultssupporting

confidence: 56%

“…Three studies were retrospective chart reviews,16 21 25 two analysed data collected prospectively in an Italian register18 28 and six were prospective trials 19 20 22 23 26 30…”

Section: Resultsmentioning

confidence: 99%

“…Four studies evaluated long-term effectiveness and safety,22 23 26 30 while only two studies focused mainly on safety evaluation 19 20…”

Section: Resultsmentioning

confidence: 99%

“…Two studies did not clarify how the AEs were collected 20 23. The Children's Sleep Habits Questionnaire was used in one study to monitor the effect of the treatment on sleep 20…”

Section: Resultsmentioning

confidence: 99%

“…In four studies investigators evaluated the severity of AEs and their relationship to drug treatment 20 23 26 30…”

Section: Resultsmentioning

confidence: 99%

See 4 more Smart Citations

Safety of medicines used for ADHD in children: a review of published prospective clinical trials

Clavenna

Bonati

2014

Archives of Disease in Childhood

View full text Add to dashboard Cite

show abstract

Section: Resultssupporting

confidence: 56%

“…Three studies were retrospective chart reviews,16 21 25 two analysed data collected prospectively in an Italian register18 28 and six were prospective trials 19 20 22 23 26 30…”

Section: Resultsmentioning

confidence: 99%

“…Four studies evaluated long-term effectiveness and safety,22 23 26 30 while only two studies focused mainly on safety evaluation 19 20…”

Section: Resultsmentioning

confidence: 99%

“…Two studies did not clarify how the AEs were collected 20 23. The Children's Sleep Habits Questionnaire was used in one study to monitor the effect of the treatment on sleep 20…”

Section: Resultsmentioning

confidence: 99%

“…In four studies investigators evaluated the severity of AEs and their relationship to drug treatment 20 23 26 30…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Safety of medicines used for ADHD in children: a review of published prospective clinical trials

Clavenna

Bonati

2014

Archives of Disease in Childhood

View full text Add to dashboard Cite

show abstract

Evaluation of Methylphenidate Safety and Maximum-Dose Titration Rationale in Attention-Deficit/Hyperactivity Disorder

2019

View full text Add to dashboard Cite

IMPORTANCE Evidence on the titration of stimulant medications for attention-deficit/ hyperactivity disorder (ADHD) is lacking. However, this lack of evidence has not prevented medication guidelines from specifying apparently arbitrary dose limitations, which could discourage clinicians from titrating methylphenidate to higher and, perhaps for some patients, more efficacious doses. OBJECTIVE To determine the evidence on dose titration and adverse events associated with dose titration of stimulants for ADHD.

show abstract

Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies

Storebø

Pedersen

Ramstad

et al. 2018

Cochrane Database of Systematic Reviews

244

161

View full text Add to dashboard Cite

Our findings suggest that methylphenidate may be associated with a number of serious adverse events as well as a large number of non-serious adverse events in children and adolescents, which often lead to withdrawal of methylphenidate. Our certainty in the evidence is very low, and accordingly, it is not possible to accurately estimate the actual risk of adverse events. It might be higher than reported here.Given the possible association between methylphenidate and the adverse events identified, it may be important to identify people who are most susceptible to adverse events. To do this we must undertake large-scale, high-quality RCTs, along with studies aimed at identifying responders and non-responders.

show abstract

12-month efficacy and safety of OROS® MPH in children and adolescents with attention-deficit/hyperactivity disorder switched from MPH

Abstract: Children and adolescents can effectively and safely be switched from IR MPH to OROS MPH with improved symptom control and compliance.

Cited by 35 publications

References 8 publications

Safety of medicines used for ADHD in children: a review of published prospective clinical trials

Safety of medicines used for ADHD in children: a review of published prospective clinical trials

Evaluation of Methylphenidate Safety and Maximum-Dose Titration Rationale in Attention-Deficit/Hyperactivity Disorder

Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies

Contact Info

Product

Resources

About